Therapeutic implications of small interfering RNA in cardiovascular diseases. (4th July 2012)

• Record Type: Journal Article
• Authors: Raghunathan, Suchi; Patel, Bhoomika M.
• Is Part Of: Fundamental & clinical pharmacology. Volume 27:Number 1(2013:Feb.)
• Page Start: 1
• Page End: 20
• Publication Date: 2012-07-04
• Subjects: Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/j.1472-8206.2012.01051.x
• Languages: English
• ISSNs: 0767-3981

Abstract

<abstract abstract-type="main" id="fcp1051-abs-0001"> <title>Abstract</title> <p>Cardiovascular diseases (CVDs) place a heavy burden on the economies of low‐ and middle‐income countries. Comprehensive action requires combining approaches that seek to reduce the risks throughout the entire population with strategies that target individuals at high risk or with established disease. Small interfering RNA (siRNA) as a functional mediator for regulation of gene expression has been evaluated for potential therapeutic targets for the treatment of various cardiovascular diseases such as hypertension, atherosclerosis, heart failure etc. The present review attempts have been made to provide a brief outline of the current understanding of the mechanism of RNAi and the delivery system and describe the therapeutic application of siRNAs and their potential for treating CVDs which are taking a heavy toll on human life.</p> </abstract>